ZARXIO 480 MCG/0.8 ML SYRINGE

What it is

ZARXIO 480 MCG/0.8 ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as filgrastim-sndz, under the trade name “ZARXIO”.

FDA gives its dosage form as injection, solution and its route as intravenous; subcutaneous.

The labeler, the company named on the label, is Sandoz Inc.

FDA’s Established Pharmacologic Class for it is Leukocyte Growth Factor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $426.73 for 0.8 mL (0.8 × $533.4125 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2025-12-17. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

The NADAC of all 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2025-12-17. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

All 2 NDCs

• 61314-0326-01 · Sandoz Inc. · $533.4125 per ML · eff. 2025-12-17 filed carried forward
• 61314-0326-05 · not listed as a package in the FDA directory · $533.4125 per ML · eff. 2025-12-17 filed carried forward

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name filgrastim-sndz with ZARXIO 480 MCG/0.8 ML SYRINGE.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $533.4125 per ML filed.

Of the 4 other products in FDA’s Leukocyte Growth Factor class priced per ML, 2 have a higher middle NADAC price and 2 a lower one. The one in the middle is ZARXIO 300 MCG/0.5 ML SYRINGE, at $531.655 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $421.41 for 0.8 mL, at an average of $526.75682 per ML in 2024 (2024-01-01 to 2024-12-31) for “Zarxio” and “Filgrastim-Sndz”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 24,638 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 0.8 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 0.8 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.